

NIH funding opportunities

05 Feb 2024 (#05)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[NOT-NS-24-025](#) Extension of [RFA-NS-24-028](#) - BRAIN Initiative Connectivity across Scales Data Coordinating Center. An additional receipt date, **August 21, 2024**, has been added and the new expiration date is **August 22, 2024**.

[NOT-NS-24-054](#) Extension of [PA-21-219](#) - Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional). The NOFO will have an additional two receipt dates and new expiration date of January 8, 2025.

[NOT-AR-24-006](#) Notice of Intent to Publish HEAL KIDS (Knowledge, Innovation and Discovery Studies): Chronic Pain Program (UC2 Clinical Trial Optional). This research will seek to advance an integrated understanding of the biological, psychological, and social factors that contribute to pediatric chronic pain. NIH is interested in pain research in infants, children, and adolescents that includes those with intellectual and physical disabilities and/or those who experience health disparities. NOFO is expected to be published in May 2024 with an expected application due date August 2024. Estimated Total Funding \$ 5 Million per year to fund 3-4 projects.

Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)

- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

[NOT-DA-25-029](#) **Strategies to Address Stigmatizing Beliefs and Policies Affecting People Who Use Drugs.** The numerous negative outcomes associated with stigma highlight the need for rigorous research on ways to address stigma and its associated consequences. Therefore, this NOSI highlights support for research to develop, adapt, and/or test strategies aimed at addressing stigma at the individual, interpersonal, and/or structural levels. Expiration Date: January 08, 2027.

[NOT-MH-24-340](#) **Impact of Policy Interventions Aimed at Addressing Social Determinants of Health to Improve Functioning and Well-being for People with Serious Mental Illnesses.** This NOSI highlights research priorities on the impact of social and economic policy interventions that address social determinants of health (SDOH) on improvements in access and engagement with mental health treatment, mental health functioning, and quality of life for people with serious mental illnesses, with special attention to understanding the underlying mediators/change mechanisms of those policies on outcomes. Expiration Date: January 09, 2026.

Notice of Funding Opportunity (NOFO)

1. [PAR-24-100](#) **National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).** This NOFO encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities.

Due dates: May 13, 2024 through to January 13, 2027. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 10 weeks before submitting the application.

2. [RFA-DA-25-032](#) **Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trial Optional).** The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing mechanistic, transdisciplinary research on social behavior and its relationships with the onset, trajectory, and impact of Substance Use Disorders (SUDs) and comorbidities.

Due dates: August 14, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIDA intends to commit a total of \$2M across this NOFO and its companion NOFOs [RFA-DA-25-033](#) and [RFA-DA-25-034](#) in FY25 to fund a total of up to three awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The award project period must be appropriate for the scope of the proposed research and cannot exceed 5 years.

3. [RFA-DK-23-011](#) **Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required).** Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a

rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels. The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use. Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

Due dates: June 27, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Letter of Intent: 30 days prior to the application due date.

Budget: National Institute of Diabetes and Digestive and Kidney Diseases ([NIDDK](#)) intends to commit \$5 million in FY 2024 to fund six awards. Application budgets cannot exceed \$500,000 in direct costs in any year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

4. [RFA-FD-24-038](#) Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional. The purpose of this NOFO is to encourage new approaches to support therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.

Due date: April 05, 2024 by 11:59 PM Eastern Time. **Letter of Intent Due:** February 19, 2024.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for (2) (two) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. Application budgets need to reflect the actual needs of the proposed project and should not exceed the \$500 000 per year in total costs (direct and indirect). The scope of the proposed project should determine the project period. The maximum project period is THREE (3) years.

<p style="text-align: center;">Faculty of Medicine and Health Sciences Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO) 009 Kth Floor, Teaching Block, Tygerberg Campus.</p>	<p style="text-align: center;">Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street</p>
<p>Enquiries: cdevries@sun.ac.za / fmhsgmo@sun.ac.za</p>	<p>Enquiries: research@sun.ac.za</p>
<p style="text-align: center;">Add “Interest in NIH opportunity” in the subject line. Add the notice number in the text of the email.</p>	